Conflicts of Interest The authors have no conflicts to disclose
Comparing 50 units across different GLP-1 medications Semaglutide is not the only GLP-1 receptor agonist on the market
The limitations of this study include the lack of longitudinal data, which restricts our ability to evaluate long-term metabolic alterations
Optimizing your health before and during pregnancy Women with obesity also face an increased risk of pregnancy complications, including preeclampsia, C-section delivery, and pregnancy loss
Alan Christianson, an endocrinologist specializing in hormone optimization, has stated that "the biggest risk with peptide therapies is not drug interactions but the patient who self-adjusts medications without lab confirmation" [17]
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial